Elevated MICs of susceptible antipseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant pseudomonas aeruginosa: Implications for dose optimization

Autores organización
Autores
- Gill C.M.
- Aktas E.
- Alfouzan W.
- Bourassa L.
- Brink A.
- Burnham C.-A.D.
- Canton R.
- Carmeli Y.
- Falcone M.
- Kiffer C.
- Marchese A.
- Martinez O.
- Pournaras S.
- Seifert H.
- Thabit A.K.
- Westblade L.F.
- Nicolau D.P.
- Wille J.
- Rezende T.T.F.
- Cekin Z.
- Malkocoglu G.
- Gijón D.
- Tarakmeh L.A.
- Chu C.Y.
- Opperman C.J.
- Tootla H.D.
- Moodley C.
- Coetzee J.
- Vourli S.
- Dimopoulos G.
- Attallah D.M.
- Tiseo G.
- Leonildi A.
- Giordano C.
- Barnini S.
- Menichetti F.
- Di Pilato V.
- Codda G.
- Vena A.
- Giacobbe D.R.
- Satlin M.
- Curtis L.
- Fang F.
- Thomson G.
- Thomson K.
Grupos de investigación
Resumen
The present study evaluated the in vitro potency of ceftazidime and cefepime among carbapenem-resistant Pseudomonas aeruginosa isolates collected as part of a global surveillance program and assessed the pharmacodynamic implications using previously published population pharmacokinetics. When susceptible, MICs resulted at the high end of distribution for both ceftazidime and cefepime, thus 6 g/day was required to achieve optimal pharmacodynamic profiles. These findings should be considered in the clinic and for the application of CLSI susceptibility breakpoints. © 2021 American Society for Microbiology.
Datos de la publicación
- ISSN/ISSNe:
- 0066-4804, 1098-6596
- Tipo:
- Article
- Páginas:
- -
- DOI:
- 10.1128/AAC.01204-21
- Enlace a otro recurso:
- www.scopus.com
Antimicrobial Agents And Chemotherapy American Society for Microbiology
Citas Recibidas en Scopus: 7
Documentos
- No hay documentos
Filiaciones
Keywords
- Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; cefepime; ceftazidime; antiinfective agent; azabicyclo derivative; carbapenem derivative; ceftazidime; cephalosporin derivative; antibiotic sensitivity; Article; bacterium isolate; carbapenem resistant Pseudomonas aeruginosa; clinical laboratory standard; controlled study; dose calculation; drug potency; in vitro study; maximum permissible dose; MIC50; MIC90; Monte Carlo method; nonhuman; process optimization; human; microbial sensitivity test; Pseudomonas aeruginosa; Pseudomonas infection
Proyectos asociados
Determinación de la huella transcipcional de mastocitos aislados de pulpa dental humana sana y con signos clínicos de inflamación
Investigador Principal: MARIA ROSA BUENAHORA TOBAR
PCI-2019-10765 . 2020
EFECTO DEL EXTRACTO DE Trametes versicolor SOBRE EL FENOTIPO Y LA FUNCIÓN DE CÉLULAS DENDRÍTICAS HUMANAS CONDICIONADAS CON MEDIOS DE CÉLULAS DE CARCINOMA ORAL
Investigador Principal: ANDRES FELIPE CARDONA MENDOZA
PCI-2019-10805 . 2020
Creating a Latin America network for clinical training and support of pharmacists and hospital financial decision makers involved in ASPs
Investigador Principal: MARIA VIRGINIA VILLEGAS BOTERO
UEB-2020-585 . 2020
Caracterización Molecular de Aislamientos Resistentes a Ceftazidime Avibactam en Enterobacterales y Pseudomonas aeruginosa recolectados en cinco Países de América Latina. Molecular mechanisms leading to ceftazidime-avibactam resistance in Enterobacterales and Pseudomonas aeruginosa collected from five Latin American countries
Investigador Principal: MARIA VIRGINIA VILLEGAS BOTERO
UEB-2020-586 . 2020
Citar la publicación
Gill CM,Aktas E,Alfouzan W,Bourassa L,Brink A,Burnham C-AD,Canton R,Carmeli Y,Falcone M,Kiffer C,Marchese A,Martinez O,Pournaras S,Seifert H,Thabit AK,Villegas MV,Westblade LF,Nicolau DP,Wille J,Rezende TTF,Cekin Z,Malkocoglu G,Gijón D,Tarakmeh LA,Chu CY,Opperman CJ,Tootla HD,Moodley C,Coetzee J,Vourli S,Dimopoulos G,Attallah DM,Tiseo G,Leonildi A,Giordano C,Barnini S,Menichetti F,Di V,Codda G,Vena A,Giacobbe DR,Satlin M,Cardona A,Curtis L,Fang F,Thomson G,Thomson K. Elevated MICs of susceptible antipseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant pseudomonas aeruginosa: Implications for dose optimization. Antimicrob Agents Chemother. 2021. 65. (11):e01204-21. IF:5,938. (1).